Cintas Corporation vs Invesco Ltd. — how do they compare? Cintas Corporation trades at $202.82 (market cap $79.86B), while Invesco Ltd. trades at $29.67 (market cap $13.28B). The key difference: Cintas Corporation is far larger — about 6× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.86%). Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 125 Days and Invesco Ltd. for 77 Days on average.
| CTAS | IVZ | |
|---|---|---|
Market Cap | $79.86B | $13.28B |
Volume | 1,323,583 | 3,698,033 |
Sector | Industrials | Financials |
52-Week High | $216.53 | $33.31 |
52-Week Low | $163.55 | $22.44 |
Typical Hold Time | 125 Days | 77 Days |
Enterprise Value | $82.33B | $23.45B |
Dividend Yield | 1.03% | 2.86% |
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $202.25, up 2.57% today, reflecting strong momentum after recent earnings beats. The stock shows bullish technical signals, with price above key moving averages and support at $198. Fundamentally, Q1 2027 revenue reached $3.01 billion, a 10.9% YoY increase, with earnings per share of $1.39 beating estimates. The company raised fiscal 2027 guidance, signaling confidence in continued organic growth and margin expansion, supported by a robust business model in uniform rental and workplace services.
The outlook remains positive given upward earnings revisions and a consensus price target of $234.60, implying 16% upside. However, risks include elevated valuation multiples (P/E 39.67) and sensitivity to economic cycles affecting corporate spending. Analyst sentiment is mixed with 40% buy ratings, but institutional ownership trends and dividend growth underscore long-term stability. Execution on guidance and margin sustainability are key to maintaining premium valuation.
Invesco (IVZ) trades at $29.66, down 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. Fundamentally, the company reported negative net income of -$282 million in 2025 despite $6.38 billion revenue, though operating cash flow remains strong at $1.53 billion. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results expected October 27.
The outlook remains cautious with analyst consensus at Buy (43%) and Hold (57%), targeting $33.71. Key risks include profitability challenges and market volatility, while opportunities lie in AUM growth and dividend yield. The stock trades near the lower end of analyst targets, suggesting limited downside but requiring improved earnings for sustained recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →